Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea.
about
Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study
P2860
Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Comparative study for the effi ...... with Imatinib or Hydroxyurea.
@ast
Comparative study for the effi ...... with Imatinib or Hydroxyurea.
@en
type
label
Comparative study for the effi ...... with Imatinib or Hydroxyurea.
@ast
Comparative study for the effi ...... with Imatinib or Hydroxyurea.
@en
prefLabel
Comparative study for the effi ...... with Imatinib or Hydroxyurea.
@ast
Comparative study for the effi ...... with Imatinib or Hydroxyurea.
@en
P2093
P2860
P356
P1476
Comparative study for the effi ...... with Imatinib or Hydroxyurea.
@en
P2093
Alok Ranjan
Krishna Pandey
Parveen Jain
Rahul Chaudhary
P2860
P304
P356
10.4103/2279-042X.128145
P577
2013-10-01T00:00:00Z